A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. - Wikidata - wikimedia - TriplyDB

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

http://www.wikidata.org/entity/Q33401523

about

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Immunotherapy in gastric cancer Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine The development of immunoconjugates for targeted cancer therapy Trastuzumab emtansine for HER2-positive advanced breast cancer.Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?Twenty years of anti-HER2 therapy-associated cardiotoxicity Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates Mechanisms of action of therapeutic antibodies for cancer Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.Emerging therapies for breast cancer Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer.Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts Treatment of HER2-positive breast cancer.Antibody Drug Conjugates: Nonclinical Safety Considerations.Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.A Pictet-Spengler ligation for protein chemical modification Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.

P2860

Q26747729-77CD2332-F085-49CE-9EAC-B343DAB1158B Q27003258-7F7E107F-6473-4F01-9933-98D7B925942D Q27007849-B97B46DF-2635-4478-9A71-C1AB24ECF426 Q27010472-8C9BA66B-F930-4639-969C-BE8A94DC2B2D Q27015048-3342916B-8059-4A6D-9520-11445BCE3561 Q27021990-990DFE51-AE44-4037-B7E6-B3A958E366F9 Q27851917-F849B430-E49C-4F48-90A1-6E0C1EFDA98A Q28067696-AF396E29-EDE1-4CAD-846A-43C4AD011E6D Q28079391-66806E6A-0756-44F0-B0A8-FFDCA3276DB7 Q28083123-8716A397-13C8-4985-91A5-FD242E9E4D6E Q28385366-F2A3CD3A-AF13-4AD2-B447-DF21739A6B67 Q33414335-726DE681-4055-4B07-9B25-ABCF6ACF6476 Q33415375-69035E85-BE00-4550-82CD-BD12C061C22B Q33415915-11A321E1-FF86-491A-AD2C-E74FF4E4C621 Q33418305-34210091-718E-4CF6-B3E5-172D026C5B2F Q33421995-5B2477E4-7E97-408D-8635-36DA9F75A627 Q33430299-7C46FE28-82B9-49F0-AB12-D5DEE1277EB1 Q33430735-320743B9-44DA-4219-BF0E-2486A497674D Q33433942-9915B095-3973-40BF-AD86-09F00CE30113 Q33441316-F5DFCE5A-4D78-46CE-935C-D6C3955E7E91 Q33617949-D6138363-D0B3-4274-9524-6A8AB8D9D56C Q33886306-B9138DAB-DFB5-4311-A52C-D9FBB2569003 Q33954595-2F6438C7-B78F-4379-B305-14BD3D157FE0 Q34023704-1DD895C5-FA0E-4A44-B420-FC61B101240E Q34355748-320E97A7-F8D0-47DB-8FD1-E79142D00B34 Q34389275-8683C377-34F6-4D27-A914-1BE1E720BD23 Q34458036-32554C3A-4CF5-4792-865E-4934246B5C51 Q34499609-E8108584-FA53-4583-8686-1633C55DB850 Q34500802-31B0FBD8-68B1-47FB-83DA-67443533AC9F Q34714574-68506813-C54B-42E9-9794-89A79851C23E Q35740877-0DBD82AF-A1E4-465F-ACFB-35C9F4D11E8F Q35967917-6DF7058B-194E-492E-A9B6-B630AE790A22 Q36114852-B86C4223-3B33-4F3E-9551-99807F45AB7C Q36256669-FDE66721-360E-4593-A7C9-13CC6474B9B8 Q36512416-974ECB3D-FEDB-42A3-A509-C6C0D1977153 Q36585636-DEE4DE7C-E845-403A-BC71-0A745DA525F1 Q36653094-0F2F336D-F75F-4720-81C1-914D09FBE51D Q36706395-C53E6FDF-B6EE-43ED-8700-6587AE8D31D3 Q36934332-8819A6AB-B74E-4B02-B690-422705F8E4A4 Q36938365-EB3071C1-B5FF-46B5-9551-798B35D6E345

P2860

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

http://www.wikidata.org/entity/Q33401523

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@ast

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@en

type

label

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@ast

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@en

prefLabel

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@ast

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@en

P1433

Q33401523-813B2C8F-5857-4558-81B5-9B84AA265273

P1476

Q33401523-8ACF39DC-4AC1-4342-B3FE-06891D72601C

P2093

Q33401523-1CBD9392-F39F-4C05-86DF-F5D05F23A83E

Q33401523-25046E23-84BB-4B13-BAB0-51DB6EDBC2C8

Q33401523-58C710E4-68F6-4FD1-8C7C-EFF701EFB5C3

Q33401523-5926DA13-B2C6-49EC-9C06-DB2DDAE8C133

Q33401523-969DB1CE-8B58-41A6-8CF7-E7740020A6A1

Q33401523-9F9B3CD6-BB31-4107-AFBD-ACC2AD31A1AF

Q33401523-BAB4812C-46FB-4673-897F-69BAF621196F

Q33401523-CF6C316D-E4EC-42B0-8F66-9D3BDA152D1C

Q33401523-D2FC368F-8A41-49CE-B433-987832A91A3B

Q33401523-DA70A085-1780-4C1B-9FE4-E19D7544BD80

P304

Q33401523-DF613DC7-F0B6-45CA-86B1-4794B57E6F27

P31

Q33401523-EA05C402-8AB4-4475-887C-F82D2E37CE7B

P356

Q33401523-6ADFE5D0-D837-47D7-9412-F8ACE604E734

P407

Q33401523-EA1350C6-BBDC-48FB-A3AD-E74B33778411

P433

Q33401523-9F88833F-B821-40BC-8914-3AAC99964D11

P478

Q33401523-4E95E97A-B46E-4950-9943-EC058616AC66

P50

Q33401523-8C7DB47C-7907-42B4-B7A6-6B0C6C0773F7

P577

Q33401523-DA1EE047-7866-4F25-83C3-93655639D45C

P698

Q33401523-0B2E7311-0F49-4EA8-B399-82910C93B121

P356

JCO.2011.40.5902

P1433

Journal of Clinical Oncology

P1476

A phase II study of trastuzuma ...... e, a taxane, and capecitabine.

@en

P2093

Denise Yardley

http://www.w3.org/2001/XMLSchema#string

Ellie Guardino

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Gladys Rodriguez

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

Ian E Krop

http://www.w3.org/2001/XMLSchema#string

Kathy D Miller

http://www.w3.org/2001/XMLSchema#string

Lukas Amler

http://www.w3.org/2001/XMLSchema#string

Maoxia Zheng

http://www.w3.org/2001/XMLSchema#string

Michael Lu

http://www.w3.org/2001/XMLSchema#string

P304

3234-3241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.40.5902

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22649126

http://www.w3.org/2001/XMLSchema#string